Kane Biotech (TSE:KNE) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kane Biotech has seen a substantial revenue increase in the third quarter of 2024, primarily driven by the first commercial sale of its revyve™ Antimicrobial Wound Gel. The company also announced significant corporate developments, including new distribution agreements and regulatory approvals, positioning it well for future growth in the wound care market.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
